Meeting
2019 Genitourinary Cancers Symposium
A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.
Authors
Fred Saad
Centre Hospitalier de l’Université de Montréal, Université de Montréal, Montréal, QC, Canada
Fred Saad , Anil Kapoor , Armen G. Aprikian , Richard Casey , Michele Caveen , Maureen Reiner , Brad Gillesby , Antonio Finelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 161)
DOI
10.1200/JCO.2019.37.7_suppl.161
Abstract #
161
Poster Bd #
G4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2022 ASCO Genitourinary Cancers Symposium
Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial.
First Author: Kouji Izumi
Poster
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
First Author: Jordan Bauman
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
First Author: Naoki Fujita